Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
05 déc. 2018 16h30 HE
|
OptiNose, Inc.
YARDLEY, Pa., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights
13 nov. 2018 07h00 HE
|
OptiNose, Inc.
Company reports third quarter net XHANCE revenue of $1.9 million Company reports 42% monthly XHANCE prescription growth from August to October Conference call and webcast to be held today at 8:00...
Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018
31 oct. 2018 16h30 HE
|
OptiNose, Inc.
Conference Call and Webcast Scheduled for Tuesday, November 13 at 8:00 a.m. Eastern Time YARDLEY, Pa., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...
Optinose to Highlight Data at Two Upcoming Scientific Meetings
03 oct. 2018 07h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the 2018 Cantor Global Healthcare Conference
24 sept. 2018 16h30 HE
|
OptiNose, Inc.
YARDLEY, Pa., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Second Quarter 2018 Financial Results and Recent Operational Highlights
14 août 2018 07h00 HE
|
OptiNose, Inc.
Company reports second quarter net product sales of $1.3 million and that more than 2,600 physicians have prescribed XHANCE since launch Conference call and webcast to be held today at 8:00 a.m....
Optinose to Report Second Quarter 2018 Financial Results and Corporate Updates on August 14, 2018
07 août 2018 17h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
02 juil. 2018 17h11 HE
|
OptiNose, Inc.
YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals
21 juin 2018 16h30 HE
|
OptiNose, Inc.
NAVIGATE II: XHANCE produced significant improvement in both co-primary outcome measures, congestion/obstruction at week four and total polyp grade at week 16 EXHANCE-12: Over one year of treatment,...
Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The Year 2018 in Greater
15 juin 2018 14h05 HE
|
OptiNose, Inc.
YARDLEY, Pa., June 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...